Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Clinical trial NCT06428396 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06428396
Sponsor: Merck Sharp & Dohme LLC
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Breast Cancer

Start date: 2024-11-27
Primary completion: 2027-05-05
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.